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Abstract
Crohn’s disease (CD) is a chronic inflammatory condition that can affect any part of the
gastrointestinal tract. The human gut microbiome is altered in patients with Crohn’s
disease. This knowledge has led to research directed at altering the microbiome for
therapeutic  potential.  Probiotics  are an attractive therapy,  both from a researcher’s
perspective and also from the patients’ perspective. In this chapter, we will review the
current clinical evidence for the use of probiotics in the treatment of Crohn’s disease.
These studies are divided into three categories: induction of remission, maintenance of
medically  induced  remission,  and  maintenance  of  surgically  induced  remission.
Unfortunately, there is insufficient evidence to support the use of probiotics in the
management of Crohn’s disease at this time.
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1. Introduction
Crohn’s disease (CD) is one of the inflammatory bowel diseases (IBD) that can affect any part
of the intestinal tract, from the gums to bum. This disease was first described in 1932 as
regional ileitis; at that time, treatment was palliative [1]. It was known even then that this
disease could cause perforation and fistulas. Crohn’s disease is characterized by transmural
inflammation, ulceration—from superficial aphthous ulcers to those that are deep and cause
penetration, with skip lesions, and granulomas on pathological specimens. The pathogenesis
of Crohn’s disease is multifactorial—genetic susceptibility, altered host immune response,
interplay with the environment, and altered gut microbiome.
The mainstay of treatment for Crohn’s disease is medical with surgical intervention reserved
for managing strictures and fistulas and for medically refractory disease. While there is no cure
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for Crohn’s disease, therapies are used to induce remission and maintain remission. When
surgery is used to induce remission, strategies to prevent post-operative recurrence are
important. Standard therapies for Crohn’s disease focus on altering the immune system with
corticosteroids, immunosuppressants, and biologic therapies that are directed at altering the
immune system. Knowledge of the role of the enteric bacteria in the pathogenesis of Crohn’s
disease has led to interest in using probiotics for the treatment of this disease.
2. The altered microbiome in Crohn’s disease
The microbiome of patients with Crohn’s disease is known to be different than healthy controls.
This difference is frequently called dysbiosis. The faecal microbiota in patients with CD has
less complexity compared to the healthy controls [2]. Further, the temporal stability of
dominant species of bacteria is lower in patients with CD compared to the controls [3]. Biopsy
specimens of patients with IBD showed an abundance of Enterobacteriaceae compared to the
controls [4]. Interestingly, in another study, biopsies from affected and unaffected areas of
tissue of patients with IBD show significant differences in diversity [5]. It is uncertain whether
the changes in the microbiota in IBD contribute to the disease development or the reverse is
true. The Genetics, Environmental, Microbial (GEM) Project is looking for insight into this
question by recruiting healthy first-degree siblings and offspring of patients with CD
(www.gemproject.ca). Alterations of the microbiome may prove to be an effective approach
for the treatment of IBD, especially if these changes in microbiome precede the onset of the
disease.
Altering the microbiome as a way to treat active Crohn’s disease (induce remission) or maintain
remission induced by surgery or medications is being explored. Current methods to alter the
microbiome include diet, antibiotics, probiotics, and more recently faecal microbial transplan-
tation.
The use of enteral nutrition (EN) to induce remission in children with Crohn’s disease has long
been described [6]. In the recent ECCO/ESPGHAN guidelines, exclusive enteral nutrition is
recommended as first-line therapy to induce remission in children with active luminal CD [7].
Recently, a systematic review of EN to maintain remission has also shown that EN is associated
with a lower risk of relapse compared to a regular diet (34% vs. 64%, p < 0.01) [8]. Dietary
therapy has rapid effects on microbiota composition and reduces inflammation [9].
Antibiotic exposure is known to be associated with dysbiosis, and this dysbiosis has been
shown to be decreased with reduced intestinal inflammation in CD [9]. There are several
studies looking at the antibiotics for the treatment of luminal Crohn’s disease with some
evidence to support the use of ciprofloxacin and metronidazole in treating luminal disease [10].
In surgically induced remission, antibiotics, in particular metronidazole and ornidazole, can
reduce recurrence rates at 1 year [10].
Finally, probiotics are being used to attempt to alter the microbiome in patients with IBD. To
date, the studies looking at probiotics to treat Crohn’s disease have shown a rather modest
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benefit [11]. Nevertheless, patients and physicians alike remain interested in the potential of
probiotics for use in the management of IBD. In a focus group study of patients with IBD and
IBS conducted at the Cleveland Clinic, patients viewed probiotics favourably and understood
them as a natural, low-risk option [12]. In addition to this, they had many unanswered
questions about the use of probiotics. This further supports the need for health care providers
to know and understand the evidence for the use of probiotics in the treatment of Crohn’s
disease.
3. Probiotic therapy in Crohn’s disease
Medical treatment of Crohn’s disease is often classified into the following categories: (1)
induction of remission, (2) maintenance of medically induced remission, and (3) maintenance
of surgically induced remission. The results of the available randomized and open-label clinical
trials examining the effectiveness of probiotics will be presented for each of these three
categories. In Crohn’s disease, traditionally, clinical indices have been used to assess clinical
efficacy for the treatment of Crohn’s disease, with an emphasis on improving patient’s
symptoms and quality of life. The Crohn’s disease activity index (CDAI) is most commonly
used with values <150 being associated with remission and scores >450 indicating severe
disease [13]. More recently, mucosal healing has emerged as an important and objective
treatment endpoint in evaluating the efficacy for the treatments of Crohn’s disease [14]. The
majority of the studies of probiotics in Crohn’s disease have used clinical endpoints, with the
exception of the post-operative recurrence studies [15].
3.1. Induction of remission
The data to support the use of synbiotics or probiotics to treat active Crohn’s disease are limited.
In an open-label trial, Fujimori et al. examined the effect of synbiotic therapy (Bifidobacterium
breve, Lactobacillus casei, Bifidobacterium longum, and psyllium) in 10 CD patients with active
disease, the CDAI significantly improved (255-136, P = 0.009) with only two of the six res-
ponders successfully discontinuing steroid therapy in 13 months [15]. In a randomized
controlled study of a different synbiotic (Bifidobacterium longum and Synergy 1 [inulin and
oligofructose]), the CDAI of 35 patients with active CD also significantly improved at 6 months
in the treatment group (219 ± 78 vs. 147 ± 74, p = 0.02) but not in the placebo group (249 ± 78
vs. 233 ± 155, p = 0.81) [16]. A criticism of this study is that baseline CDAI of the treatment
group was lower than the placebo group, even though this difference was not statistically
different (p = 0.35). Schultz et al. treated 11 CD patients with antibiotics and a tapering course
of steroids. At 2 weeks, antibiotics were discontinued and the subjects were randomized to
receive either Lactobacillus GG or placebo but found no difference in remission rates between
the groups (80% vs. 83%) [17]. Twenty-five patients with mild/moderately active CD taking 5-
acetylsalicylic acid (5-ASA) were treated in an open-label study with Lactobacillus salivarius for
6 weeks which resulted in significant improvement in clinical disease activity (217 vs. 150, p <
0.05) [18]. In a small open-label study of four paediatric CD patients using Lactobacillus GG for
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6 months, Gupta et al. [19] showed a significant improvement in paediatric CDAI scores (p <
0.05) and 3/4 were able to taper their steroids.
In a recent meta-analyses that included 12 randomized trials studying remission induction in
active IBD, subgroup analyses for CD showed no significant benefit with probiotics for
inducing remission or response in active disease (p = 0.35, RR = 0.89) [20]. Overall, based on
current evidence, probiotics cannot be recommended for use to induce remission in patients
with active Crohn’s disease.
3.2. Maintenance of medically induced remission
To date, the only study that demonstrated a statistically significant prolongation of medically
induced remission in CD was that of Guslandi et al. [21], who compared Saccharomyces boulardii
plus mesalamine versus mesalamine alone for 6 months. In this study, only 6.25% patients
treated with probiotic plus mesalamine had a clinical relapse compared to 37.5% treated with
mesalamine alone (p = 0.04). Prior to this, Malchow [22] completed a randomized, double-
blind, placebo-controlled study of Escherichia coli Nissle 1917 in a group of 28 patients with
active colonic CD with corticosteroid-induced remission. In this study of the patients that were
able to successfully wean from steroids, 30% of the probiotic group relapsed compared to 70%
of the controls; this difference was not statistically different.
Currently, in regards to Lactobacillus, there continues to only be one randomized, placebo-
controlled trial in the adult population to evaluate if Lactobacillus GG is effective in inducing
or maintaining medically induced remission [17]. All patients received a 2-week course of
ciprofloxacin and metronidazole, along with a 12-week tapering course of corticosteroids
starting at 60 mg. Eleven patients with moderate to active CD were initially enrolled to receive
probiotic, LGG (2 × 109CFU/day), or placebo at week 2 of the study for six months. The primary
endpoint was sustained remission defined as the absence of relapse at the 6-month follow-up
visit. Relapse was defined as an increase in CDAI of >100 points. This study did not identify a
benefit of Lactobacillus GG in maintaining remission in CD. However, a limitation of this study
was inadequate power as the sample size was only 11 patients with only 5/11 patients com-
pleting the study. Of the five patients who remained in the study, two patients in each of the
placebo and the probiotic groups had sustained remission. Systematic reviews and meta-
analyses have also identified no benefits of Lactobacillus as a single probiotic agent in main-
taining remission or preventing clinical or endoscopic relapses [20, 23, 24].
Bousvaros et al. [25] conducted a study in which 75 paediatric CD patients in remission were
randomly assigned to receive either Lactobacillus rhamnosus strain GG (LGG) or placebo for 2
years. There were no significant differences between the groups with respect to the median
time to relapse (9.8 vs. 11.0 months, p = 0.24 for the LGG and placebo groups, respectively) or
the number of patients who relapsed (p = 0.18).
Most recently, Bourreille et al. [26] have conducted the only randomized-controlled trial
(FLORABEST) in 165 patients with corticosteroid- or aminosalicylate-induced remission;
patients were randomized to Saccharomyces boulardii or placebo for 1 year. The rate of relapse
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was similar between the groups (47.5% were in the S. boulardii group vs. 53.2% were in the
placebo group, p > 0.05) with no difference in the median time to relapse.
In a recent meta-analysis from 2014, subgroup analyses assessing seven studies recruiting CD
patients revealed no significant difference in maintaining clinical remission with probiotics
and placebo. The strains assessed included E. coli Nissle and Bifidobacterium longum [20]. Study
limitations include the lack of consistency with probiotic, dose, concurrent IBD medications
and the absence of endoscopic assessment of remission. Thus, there remains inconclusive
evidence to support the use of probiotics to maintain remission in Crohn’s disease and well-
designed studies are required.
3.3. Maintenance of surgically induced remission
Recurrence of Crohn’s disease post-resection continues to be an ongoing challenge in its
management. The Rutgeerts score is a widely accepted scoring system for assessment of
endoscopic recurrence post-ileocolonic resection. A number of studies have looked at different
probiotics to prevent disease recurrence in CD patients with surgically induced remission.
Campieri et al. [27] reported in an abstract, a study of 40 patients treated with either rifaximin
for 3 months followed by VSL#3 for 9 months versus mesalamine for 12 months, endoscopic
recurrence rates at 1 year (80% for the probiotic group vs. 60% mesalamine group, no statistics
reported). In another study of VSL#3, this combination product significantly reduced CD post-
operative recurrence when the probiotic was administered immediately after surgery but not
when administered some months after surgery [28]. In this multicenter study, 120 patients were
randomly assigned to receive VSL#3 or placebo for 90 days, after 90 days of randomized
treatment, all patients demonstrating either no or mild endoscopic recurrence were given
VSL#3 for the remainder of this 365-day study. Colonoscopy was performed at days 90 and
365 to assess for endoscopic recurrence. At day 90, rates of severe endoscopic recurrence were
similar (9.3% for the VSL#3 vs. 15.7 for placebo, p = 0.19). Endoscopic assessment at 365 days
showed a trend toward less severe endoscopic recurrence if treated with VSL#3 for the year
than those treated later (10% vs. 26.7%, p = 0.09).
In a randomized, double-blind trial by Prantera et al. [29], 40 patients received either Lactoba‐
cillus GG versus placebo following surgical resection for 1 year, there were no significant
differences in clinical recurrence (16.6% vs. 10.5%, p = 0.948), or endoscopic recurrence (60%
vs. 35.2%, p = 0.297) between the two groups. In 2006, Marteau et al. [30] conducted a larger
trial (n = 98) over 6 months to investigate the efficacy of a single probiotic strain (Lactobacillus
johnsonii LA1) to prolong the time to relapse in CD patients. The per protocol analysis
confirmed that there was no significant difference between the two cohorts regarding endo-
scopic recurrence of disease at 6 months (64% vs. 49%, p = 0.15). Similarly, Van Gossum et al.
[31] examined the efficacy of this same probiotic Lactobacillus johnsonii LA1 in a multicenter
randomized controlled trial to prolong the time to relapse following elective ileocecal resection.
Subjects were randomized to probiotic or placebo for 12 weeks at which time endoscopic
recurrence was assessed; the proportion of patients with severe recurrence was similar (21%
vs. 15%, p = 0.33).
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In 2007, Chermesh et al. [32], conducted a small trial of Synbiotic 2000 (a commercial mixture
containing four probiotics and four prebiotics) versus placebo. A total of 30 subjects were
randomized 2:1 to probiotic: placebo. During the 2-year study, 21 subjects dropped out leaving
only nine patients for analysis. No significant difference was found.
In summary, the evidence to support the use of probiotics to prevent recurrence in surgically
induced remission is lacking.
4. Conclusion
The role of the microbiome as part of the pathogenesis of Crohn’s disease has provided the
impetus for much of the research at ways to influence the microbiome in patients with Crohn’s
disease. Probiotics, along with antibiotics, diet, and faecal microbial transplant, are being
studied as options to treat this chronic inflammatory disease. Probiotics are appealing to
patients likely due to them being perceived as natural, low-risk therapies for the treatment of
IBD, in contrast to standard therapy which focuses on modulating the immune system. To
date, the evidence to support the use of probiotics to induce and maintain remission in Crohn’s
disease is disappointing. Problems with probiotic research include the lack of knowledge about
which probiotic to choose and at what dose. For probiotics to have a role in the management
of Crohn’s disease, more research is needed to align the pathogenic mechanism of the disease
with the actions of the probiotics.
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